Claims

1. (*S*)-4-Amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]-pyrimidin-4-yl)piperidine-4-carboxamide, (i.e. Compound (I)), in crystalline form.

~~2. Compound (I) in crystalline form, according to claim 1~~, in the form of Form B.

~~3~~2. Compound (I) in crystalline form, according to claim ~~2~~1, in the form of Form B wherein said Form B has an X-ray powder diffraction pattern with at least three specific peaks at about 2-theta = 12.3°, 15.0° and 19.2°.

~~4~~3. Compound (I) in crystalline form, according to claim ~~2~~1, in the form of Form B wherein said Form B has an X-ray powder diffraction pattern with specific peaks at about 2-theta = 10.0, 12.3, 15.0, 17.1, 19.2 and 24.4°.

~~5~~4. Compound (I) in crystalline form, according to claim ~~2~~1, in the form of Form B wherein said Form B has an X-ray powder diffraction pattern substantially the same as that shown in Figure 3.1.

~~6~~5. Compound (I) in crystalline form, according to claim ~~2~~1, in the form of Form B wherein said Form B has an X-ray powder diffraction pattern substantially the same as that shown in Figure 3.2.

~~7~~6. A pharmaceutical composition which comprises Compound (I) in crystalline form, as claimed in any one of claims 1 to ~~6~~5, in association with a pharmaceutically-acceptable diluent or carrier.

~~8~~7. Compound (I) in crystalline form, as claimed in any one of claims 1 to ~~6~~5, for use as a medicament.

~~9~~8. The use of Compound (I) in crystalline form, as claimed in any one of claims 1 to ~~6~~5, for the preparation of a medicament for the treatment of cancer.

~~10~~9. Use of a therapeutically effective amount of Compound (I) in crystalline form, as claimed in any one of claims 1 to ~~6~~5 in the manufacture of a medicament for treating breast cancer, prostate cancer, or gastric cancer.

~~11~~10. A pharmaceutical composition which comprises Compound (I) in crystalline form as claimed in any one of claims 1 to ~~6~~5, in association with microcrystalline cellulose, mannitol, croscarmellose sodium and magnesium stearate.

~~12~~11. A pharmaceutical tablet which comprises from 50 to 500 mg of Compound (I) in crystalline form as claimed in any one of claims 1 to ~~6~~5, in association with one or more pharmaceutically acceptable excipients.

~~13~~12. A pharmaceutical tablet which comprises from 0.5 to 2% by weight of magnesium stearate, from 2 to 5% by weight of croscarmellose sodium, from 15 to 60% by weight of Compound (I) in crystalline form as claimed in any one of claims 1 to ~~6~~5, microcrystalline cellulose and mannitol, wherein the relative weights of microcrystalline cellulose and mannitol within the tablet are in a ratio of from 3:1 to 1:1 and wherein the amount of Compound (I) in crystalline form within the tablet is from 50 to 500 mg.